US 12,404,300 B2
Mitochondria-targeting peptides
Guozhu Zheng, Lexington, MA (US); Mark J. Bamberger, South Glastonbury, CT (US); and Inese Smukste, Weston, MA (US)
Assigned to Stealth BioTherapeutics Inc., Needham, MA (US)
Appl. No. 17/414,103
Filed by Stealth BioTherapeutics Inc., Needham, MA (US)
PCT Filed Nov. 19, 2019, PCT No. PCT/US2019/062283
§ 371(c)(1), (2) Date Jun. 15, 2021,
PCT Pub. No. WO2020/131282, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/892,939, filed on Aug. 28, 2019.
Claims priority of provisional application 62/781,153, filed on Dec. 18, 2018.
Prior Publication US 2022/0041653 A1, Feb. 10, 2022
Int. Cl. C07K 5/107 (2006.01); A61P 9/10 (2006.01); C07K 7/06 (2006.01); A61K 38/00 (2006.01)
CPC C07K 5/1016 (2013.01) [A61P 9/10 (2018.01); C07K 7/06 (2013.01); A61K 38/00 (2013.01)] 22 Claims
 
1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
Aaa1 is an amino acid residue selected from the group consisting of:

OG Complex Work Unit Chemistry
Aaa2 is an amino acid residue selected from the group consisting of:

OG Complex Work Unit Chemistry
Aaa3 is an amino acid residue selected from the group consisting of:

OG Complex Work Unit Chemistry
Aaa4 is an amino acid residue selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
R1a and R4d are each independently (C1-C6)alkyl;
R2a, R2b, R2e, R3a, R3b, R4a, R4b, R4c are each independently selected from the group consisting of H and (C1-C6)alkyl; and
Ra, Rb, R2c, and R2d are each independently selected from the group consisting of H, (C1-C6)alkyl, C(O)((C1-C6)alkyl), C(O)((C1-C6) haloalkyl), C(O)O((C1-C6)alkyl), and C(O)O(aryl (C1-C6)alkyl).